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Abstract. The objective of the present study was to evaluate 
the role of P-selectin in patients with cancer with suspected 
thromboembolic events (TEEs). Patients with cancer have a 
four times greater risk of developing TEEs. P-selectin is a 
glycoprotein that has the function of facilitating the interaction 
(adhesion) of leukocytes with the endothelium, or with plate-
lets. There is a well‑defined relationship between P‑selectin 
and thrombosis; however, it is likely that the cut-off value 
of P-selectin for patients with cancer should be considered 
differently from that of the general population. In the present 
report, a prospective cross-sectional study was performed 
with patients of the Cancer Hospital of Barretos who were 
suspected of having TEEs. Among the 178 study participants, 
167 (93.82%) were suspected of having deep vein thrombosis, 
while 59 of them (35.33%) were confirmed as such; and 11 
(6.18%) were suspected of having pulmonary thromboem-
bolism, while 3 of them were confirmed as such (27.69%). 
The mean results obtained were: P-selectin, 25.37 ng/ml; 
and D-dimer, 2,181.22 ng/ml. The P-selectin levels aver-
aged 33.60 ng/ml with the confirmed TEE group compared 
with 20.40 ng/ml with the unconfirmed TEE group, with a 
standard deviation of 23.35 compared with 6.92 (P<0.001); 
and the level of D-dimer was 4,615.38 ng/ml compared with 
977.52 ng/ml, with a standard deviation of 6,460.54 compared 
with 2,145.50 (P<0.001). Multiple logistic regression adjusted 
for distant metastases and the Eastern Cooperative Oncology 
Group (ECOG) score (2,3 and 4) were constructed. The cut-off 
value of P‑selectin for patients with cancer was identified to 
be different from that reported in the literature for the general 
population, and the models using D-dimer and P-selectin 
therefore have been demonstrated to be a potentially useful 
tool to be used in a panel of tests to predict TEEs, either inde-
pendently or in a prediction score.
Introduction
The legendary pathologist, Rudolph Virchow, identified more 
than a century ago the three most important pathophysi-
ological mechanisms for the development of thrombosis (i.e., 
hypercoagulability, blood stasis and endothelial injury) (1), 
parameters that are still relevant for, and of interest to, the 
scientific community. The incidence of deep vein throm-
bosis (DVT) in the United States is ~117 cases per 100,000 
people/year (2); several published studies have included 
numbers that varied between 43 and 145 cases per 100,000 
people/year; and pulmonary embolism (PE) has been identi-
fied in 20‑65 cases per 100,000 people/year (2-7). In ~15% 
of these cases, the thromboembolic events (TEEs) are the 
first manifestation of a neoplasia (8). Patients with cancer 
have a four times greater risk of developing DVT compared 
with patients without cancer. If a person is on chemotherapy, 
this risk increases to up to six times compared with a person 
without cancer (9). Moser et al (10) have demonstrated that 43% 
of the patients treated for DVT without symptoms for TEEs 
had abnormal thorax scans, suggesting a high likelihood of 
lung embolism. Furthermore, ~70% of the patients had indica-
tions of PE, suggesting DVT without presenting symptoms had 
been identified (11,12). The rates of recurrence of idiopathic 
DVT are ~7.8% per year, but if a patient has active cancer, the 
recurrence rate will be much higher (~14% per year), reaching 
a percentage of 30.4% of recurrence in 8 years (9,13,14).
There are several risk factors for the development of 
TEEs, including an advanced age, obesity, any previous TEE, 
surgery, trauma, antiphospholipid antibody, thrombophilia, 
nephrotic syndrome, heart failure, chronic immobilization, 
central venous catheter and active neoplasia, predominantly 
in association with chemotherapy (15-18). Approximately 
25-50% of cases are considered to be idiopathic, i.e. these 
cases do not have a well‑defined etiological cause to explain 
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the occurrence of the TEE (9,19). TEE in patients with cancer 
is a major complication, and patients may be even worse off as 
a consequence of the TEE relative to the cancer itself.
A plethora of biological markers have been studied in order 
to gain an improved understanding of TEE in patients with 
cancer. The D-dimer is such a biomarker. D-dimer is a product 
of the degradation of fibrin, and has proven to be very useful 
in excluding PE in patients with a low PE pretest probability 
score (20,21). However, in certain situations, such as in cases 
of surgery, acute myocardial infarction and septicemia, the 
D-dimer value may be shown to be reduced, as occurs in patients 
with cancer (22,23). P-selectin is a glycoprotein present in the 
endothelium and platelets (24,25) that, through the media-
tion of tumor necrosis factor-α (TNF-α) and interleukin-1 
(IL-1), binds to leukocytes, primarily to neutrophils (26), 
with the function of facilitating the interaction (adhesion) 
of leukocytes with the endothelium or with platelets (27), 
besides exerting different roles in various stages of inflamma-
tion (28). A well‑defined association exists between elevated 
serum levels of P-selectin and thrombosis (29). An elevated 
level of P-selectin is a useful parameter to identify patients 
who are at risk of thrombotic events, showing an odds ratio 
of 2.6 for patients with serum levels of P-selectin >53.1 ng/dl 
after having been adjusted for age, sex, surgery, chemotherapy 
and radiotherapy. However, there are a group of patients who 
present abnormal values of P-selectin without TEEs (30-32). 
In all likelihood, the cut-off value of P-selectin for patients 
with cancer should be considered differently from that of the 
general population, given the important role of this protein in 
hematogenic metastasis (33).
Studies of TEEs in populations of cancer biomarkers remain 
scarce, particularly with respect to the role of P-selectin, where 
more accurate investigations are required to test the impact of 
P-selectin evaluation on TEE early diagnosis. The objective 
of the present study was to evaluate the role of P-selectin in 
patients with cancer suspected of TEE, and to compare these 
values with the classical parameters of hematological altera-
tions in this population.
Patients and methods
The present study is a cross-sectional study with a prospective 
collection of data, performed with patients with cancer 
suspected of having TEEs, who were monitored or underwent 
treatment in the Cancer Hospital of Barretos (HCB) between 
November 2013 and June 2014. Patients over 18 years of age 
agreed to undergo imaging tests in order to confirm or exclude 
the diagnosis of TEEs. The Research Ethics Committee of the 
Barretos Cancer Hospital approved the present study.
Laboratory tests. Peripheral blood samples were collected 
from all the patients after signing a consent form that explained 
the proposals of this project. The following tests were 
performed: Fibrinogen (FBN) plasma levels were determined 
according to dosage by the Clauss method using an automated 
coagulation analyzer (Tcoag Destiny Max™; Trinity Biotech 
UK, Bray, Co. Wicklow, Ireland) and a specific kit (Tcoag 
TriniCLOT™; Trinity Biotech UK). Expected values ranged 
from 175-400 mg/dl (34). TNF-α levels were determined by 
quantitative measurement, using a solid-phase, sequential 
chemiluminescent immunometric assay (IMMULITE® 1000 
Chemiluminescent Technology; Siemens Medical Solutions 
Diagnostics, Los Angeles, CA, USA). Expected values were 
up to 8.1 pg/ml. Levels of activated Factor Xa (AFXa) were 
assessed using a chromogenic method (Tcoag Destiny Max™; 
Trinity Biotech UK) and a specific kit (Tcoag TriniCLOT™; 
Trinity Biotech UK). Ultra-sensitive C-reactive protein 
(hsCRP) was quantified using monoclonal antibodies with an 
immunonephelometric method on automated equipment (BN 
Systems II, incorporating a Cardio Phase hsCRP kit; Siemens 
Healthcare Diagnostics Products, Marburg, Germany). The 
reference range was <1.0 mg/l for risk assessment of vascular 
disease, and <5.0 mg/l for an evaluation of inflammatory/infec-
tious processes. IL-6 levels were determined by quantitative 
measurement using a solid-phase, sequential chemiluminescent 
immunometric assay (IMMULITE® 1000 Chemiluminescent 
Technology; Siemens Medical Solutions Diagnostics). The 
expected values were up to 5.9 pg/ml. The D-dimer concentra-
tion was evaluated using an immunoturbidimetric method, by 
an agglutination test: Polystyrene microparticles with fibrin 
degradation products containing the D-dimer were quantita-
tively determined in human citrated plasma. The equipment 
used was a coagulation analyzer (Tcoag Destiny Max™; 
Trinity Biotech UK), and the reference value was 500 ng/ml. 
P-selectin levels were determined quantitatively using enzyme 
immunoassay/enzyme-linked immunosorbent assay, with an 
immune kit (IBL IMMUNO-Biological Laboratories, Co. 
Ltd., Fujioka, Japan). Expected values of P-selectin in the 
serum ranged from 67-233 ng/ml [in the plasma (EDTA) 
they range from 50-233 ng/ml; in the plasma (citrate), from 
92-212 ng/ml; in the plasma (heparin), from 60-188 ng/ml. As 
our protocol was performed with plasma, a value of 233 ng/ml 
was accepted as being normal].
Sample size. The sample size was calculated taking into account 
a study by Ramacciotti et al (35) that evaluated 178 patients 
suspected of DVT; the authors of that study identified that, 
in 62 cases, there was confirmation of the event. Comparing 
the serum levels of P-selectin from the groups with or without 
DVT, a significant difference was observed between them. 
Considering a significance of 5% and a test power of 90%, 
and clinical relevance with values ranging from 20-30 ng/dl 
between the groups, the present authors calculated that there 
were 24-55 cases of TEEs, as shown in Table I. Statistical 
analyses were performed using IBM-SPSS software, version 
21 (IBM SPSS, Inc., Armonk, NY, USA). P<0.05 was consid-
ered to indicate a statistically significant value.
Results
Among the 178 patients, 108 (60.70%) were female and 
70 (39.30%) were male. Detailed socio-demographic informa-
tion concerning the patients is shown in Table II.
An examination of the clinical history of the patients 
revealed that 79 (44.38%) participants had hypertension, 
27 (15.25%) had diabetes mellitus, 56 (54.24%) had varicose 
veins, 80 (44.94%) declared that they had never smoked, 
89 (50.00%) had no restrictions on mobility, which permitted 
the inclusion of the Eastern Cooperative Oncology Group 
(ECOG) classification (36), and 86 (48.31%) and 72 (40.45%) 
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of the participants had a body mass index (BMI) within 
the normal range, according to the Brazilian Guidelines for 
Obesity, 2011 (37,38). Among the participants, 34 (19.10%) had 
been diagnosed with breast cancer, 19 (10.64%) had uterine 
cervical cancer, 11 (6.18%) had lung cancer, 11 (6.18%) had 
rectal cancer, 9 (5.06%) had prostate cancer and 99 (52.81%) 
had been diagnosed with other cancers; 175 (98.31%) of the 
patients had active cancer, 90 (50.56%) had distant metas-
tases, 87 (8.88%) were under chemotherapy treatment, and 
96 (32.32%) had completed chemotherapy; 77 (59.23%) of the 
chemotherapy treatments were palliative, and 107 (60.11%) 
patients were not submitted to radiotherapy; regarding those 
Table I. Frequency of the clinical variables of the patients enrolled in the present study.
Variable Specification Frequency %
Sex Female 108 60.70
 Male 70 39.30
Hypertension No 99 55.62
 Yes 79 44.38
Diabetes mellitus No 150 85.75
 Yes 27 15.25
Varicose veins No 81 45.76
 Yes 96 54.24
Smoking Never 80 44.94
 Refrained from smoking for >6 months 72 40.45
 Current smoker 26 14.61
Mobility No restriction on locomotion 89 50.00
 Walks unaided, but with difficulty 56 31.46
 Walks only with help from others 21 11.80
 Cannot walk, but sits out of bed 5 2.81
 Confined to bed 7 3.93
ECOG 0 31 17.42
 1 86 48.31
 2 30 16.85
 3 21 11.80
 4 10 5.62
Body mass index Underweight 12 6.74
 Normal 72 40.45
 Obesity grade I 51 28.65
 Obesity grade II 25 14.04
 Obesity grade III 12 6.74
Primary site of the cancer  Breast 34 19.10
 Uterine cervix 19 10.64
 Lung 11 6.18
 Rectum 11 6.18
 Prostate 9 5.06
 Others 94 52.81
Chemotherapy Not administered to date 48 26.97
 Ongoing 87 48.88
Clinical hypothesis Deep vein thrombosis 167 93.82
 Pulmonary thromboembolism 11 6.18
Deep vein thrombosis Negative 108 64.67
 Positive 59 35.33
Pulmonary thromboembolism Negative 8 72.73
 Positive 3 27.27
ECOG, Classification according to the Eastern Cooperative Oncology Group.
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patients for whom radiotherapy was performed, 66 (61.11%) 
had palliative radiotherapy indication, and 110 (61.80%) among 
all participants had undergone surgical treatment proposed for 
the treatment of cancer. A total of 167 participants (93.82%) 
were suspected of DVT: 59 of them (35.33%) were confirmed 
as such, and 11 (6.18%) were suspected of PE, with 3 of them 
being confirmed as such (27.69%). Six (3.41%) patients were 
treated for DVT, and one (0.57%) was receiving treatment for 
PE; one (0.56%) was receiving an oral anticoagulant treat-
ment, 5 (3.13%) were receiving injectable anticoagulants, 
15 (9.38%) were receiving an antiplatelet medicament and 5 
(5.26%) had been administered oral contraceptives (Table I). 
Upon the suspicion of a TEE, the average age of the patients 
was 56.39 years.
The mean results of the blood examinations are shown 
in Table II: Hemoglobin was 10.79 g/dl; hematocrit, 32.78%; 
platelets, 245.62 k/mm3; creatinine, 1.08 mg/dl; FBN, 
427.14 mg/dl; TNF-α, 16,76 pg/ml; activated factor X (AFXa), 
105.43%; hsCRP, 52.62 mg/l; IL-6, 22.86 pg/ml; D-dimer, 
2,181.22 ng/ml; and P-selectin was 25.37 ng/ml.
Among the cases positive for a TEE, 30 (48.39%) of the 
participants were women compared with 78 (67.24%) in 
the negative group (P=0.014) (Table III). Comparisons of 
the clinical background between the groups of the 62 posi-
tive cases and the 116 cases negative for the TEEs were as 
follows: Hypertension, 28 (45.16%) compared with 51 (43.97%; 
P=0.878); diabetes, 11 (18.03%) compared with 16 (13.79%; 
P=0.456); never used tobacco, 27 (43.55%) compared with 53 
(45.69%; P=0.527); currently smoking, 7 (11.29%) compared 
with 19 (16.38%); had no restrictions on locomotion or walking 
with difficulty, but without assistance, 47 (75.81%) compared 
with 98 (84.48%); not walking, or walking only with the help 
of others or was confined to bed, 10 (16.13%) compared with 
15 (13.80%; P=0.020); had an ECOG score of 1, 25 (40.32%) 
compared with 61 (52.59%; P=0.002); normal BMI, 32 
(51.61%) compared with 40 (34.48%; P=0.045). Further details 
concerning the data regarding treatment of the patients are 
shown in Table III.
As shown in Table IV, the mean value of hemoglobin was 
10.29 g/dl in the positive group compared with 11.05 g/dl in 
the negative group (P=0.007); the mean value of the hema-
tocrit test was 31.38% compared with 33.51% (P=0.007); 
platelets were 220.14 k/mm3 compared with 258.83 k/mm3; 
creatinine was 1.19 mg/dl compared with 1.01 mg/dl; FBN 
was 41,146 mg/dl compared with 435.81 mg/dl; TNF-α was 
14.76 pg/ml compared with 17.85 pg/ml; AFXa was 102.94% 
compared with 106.81%; hsCRP was 68.42 mg/l compared with 
43.92 mg/l (P=0.056); IL-6 was 24.83 pg/ml compared with 
21.72 pg/ml, with a standard deviation of 27.02 compared with 
48.4 (P=0.032). The mean level of D-dimer was 4,615.38 ng/ml 
compared with 977.52 ng/ml, with a standard deviation of 
6,460.54 compared with 2,145.50 (P<0.001), and the P-selectin 
averaged 33.60 ng/ml compared with 20.40 ng/ml, with a stan-
dard deviation of 23.35 compared with 6.92 (P<0.001). Further 
details are shown in Table IV.
Receiver operating characteristic (ROC) curves were used 
to determine the best cut-off point for each test, which allowed 
a comparison to be made between the two groups: Positive 
and negative for TEE. The best cut‑off point identified for the 
hemoglobin was 10 g/dl, that discriminated 23 positive partici-
pants (39.66%) from 71 (63.39%) negative ones (P=0.003); for 
hematocrit, a value >32% was the preferred cut-off, with 20 
(34.48%) positive participants compared with 74 (66.07%) 
negative (P<0.001). Similarly, the cut-off points, and numbers 
of positive and negative participants for the further variables, 
were as follows: Platelet >240 k/mm3, 20 (34.48%) positive 
compared with 38 (65.52%) negative (P=0.166); creatinine 
>0.8 mg/dl, 32 (54.24%) positive compared with 40 (39.60%) 
negative (P=0.081); FBN >393 mg/dl, 23 (44.23%) posi-
tive compared with 58 (61.7%) negative (P=0.042); TNF-α 
>12.9 pg/ml, 25 (51.02%) positive compared with 29 (32.58%) 
negative (P=0.034); AFXa, >104%, 20 (38.46%) positive 
compared with 51 (54.26%) negative (P=0.067); hsCRP 
>20.6 mg/l, 31 (60.78%) positive compared with 36 (40.00%) 
negative (P=0.018); IL-6 >11.3 pg/ml, 28 (58.33%) positive 
compared with 25 (28.09%) negative (P=0.001); and levels 
Table II. Detailed description of the laboratory findings.
   Standard  1st  3rd 
Variable n Mean deviation Minimum quartile Median quartile Maximum
Hemoglobin (g/dl) 170 10.79 2.04 4.00 9.00 11.00 12.00 16.00
Hematocrit (%) 170 32.78 5.68 11.00 28.75 34.00 47.00 44.00
Platelets (k/mm3) 170 245.62 252.00 1.00 153.00 228.00 280.75 3,026.00
Creatinine (mg/dl) 159 1.08 1.22 0.20 0.70 0.80 1.02 10.00
FBN (mg/dl) 146 427.14 145.48 45.00 331.00 413.00 514.75 830.00
TNF-α (pg/ml) 136 16.76 16.23 4.00 9.43 11.90 17.00 109.00
AFXa (%) 146 105.43 28.76 18.00 85.50 103.00 128.00 179.00
hsCRP (mg/l) 138 52.62 66.86 0.29 6.36 20.20 82.43 334.00
IL-6 (pg/ml) 120 22.86 41.75 2.00 4.28 8.85 23.45 298.00
D-dimer (ng/ml) 136 2,181.22 4,429.92 46.00 166.25 576.50 1,693.75 23,796.00
P-selectin (ng/ml) 117 25.37 16.52 3.00 16.50 20.80 27.90 120.70
FBN, fibrinogen, TNF‑α, tumoral necrosis factor-α; AFXa, activated factor Xa; hsCRP, ultrasensitive C-reactive protein; IL-6, interleukin-6.
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of D-dimer >633 ng/ml, 39 (76.47%) positive compared with 
33 (35.11%) negative (P<0.001). Finally, the cut-off point for 
P-selectin was >21.6 ng/ml, and there were 28 (63.6%) posi-
tive participants compared with 23 (31.51%) negative ones 
(P<0.0015).
In order to identify the association between the variables 
that might exert an influence on the occurrence of TEEs, 
multiple logistic regression adjusted for distant metastases and 
the ECOG score (2,3 and 4) were used. All variables with a 
P-value <0.2 were selected: Mobility, need for hospitalization, 
height, time elapsed between the first consultation and the TEE, 
body mass, hematocrit, hemoglobin, FBN, TNF-α, hsCRP, 
IL-6, D-dimer levels, and P-selectin levels. Additional multiple 
logistic regressions were constructed. The first (regression 1) 
had, as variables, distant metastasis, ECOG (scores 2, 3 and 
4), sex, and D-dimer. For this regression model, the following 
results (odds ratios) were obtained: Distant metastasis of 1.338 
(P=0.479), ECOG (scores 2, 3 and 4) of 3,039 (P=0.009), sex of 
2.557 (P=0.023) and D-dimer of 5.072 (P<0.001). The second 
logistic regression (regression 2) had, as variables, distant 
metastasis, ECOG (scores 2, 3 and 4), sex and P-selectin, which 
revealed odds ratios for distant metastasis of 2.488 (P=0.040), 
ECOG (scores 2, 3 and 4) of 4.150 (P=0.003), sex of 2.709 
(P=0.029), and P-selectin of 3.385 (P=0.007) (Table V).
The data reported above were used to prepare 4 predictive 
scoring models, ranging from 0 to 1, of which 1 indicated the 
presence of TEE and 0 indicated ‘no event'. The score predictor 
1 was built from regression 1 (with D-dimer) based on the 
sum of the approximate values of the odds ratio obtained in 
the regression. For this model, the sum is able to range from 
0 to 1 point. In the group with 0 (zero) points, the probability 
of having TEE was 5.7%; for 3 points, 23.5%; for 5 points, 
Table III. Comparison of the groups with or without thromboembolic events.
 Positive Negative
 ----------------------------- -----------------------------
Variable Specification n (%) n (%) P‑value
Sex Female 30 48.39 78 67.24 0.014
 Male 32 51.61 38 32.76 
Mobility No restrictions on locomotion 26 41.94 63 54.31 0.216
 Walks unaided, but with difficulty 21 33.87 35 30.17 
 Walks only with help from others 8 12.90 13 11.21 
 Cannot walk, but sits out of bed 2 3.23 3 2.59 
 Confined to bed 5 8.06 2 1.72 
ECOG score 0 5 8.06 26 22.41 0.002
 1 25 40.32 61 52.59 
 2 6 25.81 14 12.07 
 3 9 14.52 12 10.34 
 4 7 11.29 3 2.59 
Body mass index Low weight 5 8.06 7 6.03 0.047
 Normal 32 51.61 40 34.48 
 Overweight 13 20.97 38 32.76 
 Obesity I 9 14.52 16 13.79 
 Obesity II 1 1.61 11 9.48 
 Obesity III 2 3.23 4 3.45 
Primary site of cancer Breast 5 8.06 29 25.0 0.047
 Uterine cervix 5 8.06 14 12.07 
 Lung 4 6.45 7 6.03 
 Rectum 3 4.84 8 6.90 
 Prostate 4 6.45 5 4.31 
 Others 41 66.13 53 45.69 
Chemotherapy Not performed to date  20 32.26 28 24.14 0.463
 Ongoing 27 43.55 60 51.72 
 Treatment concluded 15 24.19 28 24.14 
Surgical treatment No 22 35.48 46 39.66 0.585
 Yes 40 64.52 70 60.34 
Clinical hypothesis Deep vein thrombosis 59 95.16 108 93.10 0.587
 Pulmonary thromboembolism 3 4.84 8 6.90
ECOG, Eastern Cooperative Oncology Group.
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39.3%; for 6 points, 50.0%; and for 8 points and 11 points, 
56.7% and 78.6%, respectively. The prediction score 2 was 
constructed using the sum of the approximate odds ratio of 
regression 2 (with P-selectin). This score ranges from 0 to 12 
points: 0 points shows a 13.6% probability of presenting TEE; 
for 2 points, 25.0%; for 3 points, 11.8%; for 4 points, 0.00%; for 
5 points, 38.5%; for 6 points, 40.0%; for 7 points, 55.6%; for 8 
points, 60.0%; for 9 points, 88.9%; for 10 points 100.0% and 
for 12 points, 83.3% (Table VI).
In order to facilitate an understanding of what the clinical 
findings signify, the predicted score 1 (with ECOG 1, 2 and 3, 
sex and D‑dimer) was classified into four levels of risk: Low 
risk (0-3 points), moderate risk (5-6 points), high risk (8 points) 
and very high risk (9 points), with the following likelihood of 
a TEE: 14.5, 40.6, 56.7 and 78.6%, respectively (Table VII). As 
in the previous model, the predictive score 4 was also prepared 
with the intention of classifying the likelihood of having a 
TEE, with reference to the predictive score 2 with P-selectin. 
The tracks were divided as follows: 0‑4 points, classified as low 
risk (14.0%); 5‑6 points, classified as moderate risk (38.9%); 
7‑8 points, classified as high risk (57.1%); and 9 or more points, 
classified as 88.2% (Table VII).
Discussion
This study corroborated, in part, data that previously reported 
the TEE as an important phenomenon to be judiciously evalu-
ated for patients with cancer subjected (or not) to treatment, as 
Table IV. Association between laboratory characteristics and thromboembolic events.
 Positive Negative
 -------------------------------------------------------------------- ------------------------------------------------------------------
Variable n Mean SD n Mean SD P-value
Hemoglobin (g/dl) 58 10.29 1.92 112 11.05 2.07 0.007
Hematocrit (%) 58 31.38 5.22 112 33.51 5.80 0.007
Platelets (k/mm3) 58 220.14 97.61 112 258.83 302.99 0.645
Creatinine (mg/dl) 59 1.19 1.40 100 1.01 1.12 0.136
FBN (mg/dl) 52 411.46 149.96 94 435.81 143.01 0.240
TNF-α (pg/ml) 48 14.76 6.48 88 17.85 19.57 0.215
AFXa (%) 52 102.94 25.72 94 106.81 30.35 0.439
hsCRP (mg/l) 49 68.42 73.39 89 43.92 61.70 0.056
IL-6 (pg/ml) 44 24.83 27.02 76 21.72 48.40 0.032
Dimer-D (ng/ml) 45 4,615.38 6,460.54 91 977.52 2,145.50 <0.001
P-selectin (ng/ml) 44 33.60 23.35 73 20.40 6.92 <0.001
SD, standard deviation; FBN, fibrinogen, TNF‑α, tumoral necrosis factor-α; AFXa, activated factor Xa; hsCRP, ultrasensitive C-reactive 
protein; IL-6, interleukin-6.
Table V. Logistic regression of thromboembolic events with the variables: Distant metastasis, ECOG (2,3 and 4), sex, and 
D-dimer (regression 1).
 CI, 95%
  -------------------------------
 Variable B SD Wald df P-value OR IL SL
D-dimer Metastasis 0.291 0.411 0.501 1 0.479 1.338 0.597 2.996
 ECOG score (2, 3 4) 1.112 0.424 6.882 1 0.009 3.039 1.325 6.973
 Sex 0.939 0.412 5.198 1 0.023 2.557 1.141 5.730
 D-dimer 1.624 0.426 14.519 1 <0.001 5.072 2.200 11.694
 Constant -2.438 0.460 28.115 1 <0.001 0.087  
P-selectin Metastasis 0.911 0.444 4.207 1 0.040 2.488 1.041 5.943
 ECOG score (2, 3 and 4) 1.423 0.479 8.825 1 0.003 4.150 1.623 1.613
 Sex 0.997 0.457 4.758 1 0.029 2.709 1.106 6.635
 P-selectin 1.219 0.452 7.280 1 0.007 3.385 1.396 8.208
 Constant -2.440 0.514 22.573 1 0.000 0.087 
B, regression coefficient; SD, standard deviation; df, degrees of freedom; the Wald test (t‑test), OR, odds ratio; CI, confidence interval; LI, 
inferior limit, LS, superior limit; ECOG, classification according to the Eastern Cooperative Oncology Group.
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we have identified a total of 36.03% of confirmed TEEs. Such 
events are particularly significant considering that, among 
297 patients recruited in a period of 231 days, the occurrence 
of thromboembolism was confirmed for 107 of them, with an 
average of a TEE confirmed every 2.15 days. These figures 
confirm the importance of this issue, and the urgency to 
improve strategies of prevention and early diagnosis.
The average age of the patients was 56.58 years, and there-
fore no relevant difference between groups with or without 
a TEE was observed. Nevertheless, there was a statistically 
significant difference between the sex. In men, the positive 
group represented 48.62%, whereas for the negative group, 
it was 34.64%. However, these data are contestable, since 
the TEE diagnostic confirmation occurred in 51.37% of the 
women and 48.62% of the men (P=0.028), which corroborated 
data published previously in the literature (4,5,9,14).
No difference was identified between the groups associ-
ated with systemic arterial hypertension, diabetes mellitus or 
smoking. Regarding the group positive for TEE, the percentage 
with a hypertensive condition was 40.43%, consistent with the 
values identified in the general population, ranging from 22.3 
to 43.9% and averaging 32.5%; however, in the population 
aged 60-69 years, these values could increase up 50%, and 
>70 years, may reach 75% (39-41). The frequency of diabetes 
was 14.89%, higher than the average observed in the Brazilian 
population (5%). However, analyzing higher age groups, for 
example, between 70 and 79 years, the percentage can rise up 
to 17.5% (42). This is a relevant fact in this population, since 
the association between diabetes and abnormal vascular events 
has been firmly established. Active smoking was identified in 
12.46% of the patients, slightly below the national average, 
which is 16.1% (43). It is known that smoking is an independent 
risk factor for TEEs (16,44); however, the difference identified 
(8.26% in the positive group and 14.98% in the negative group) 
could be accounted for by chance, since the P-value was not 
significant (P=0.234).
Table VI. Score predictors of a thromboembolic event, based on logistic regression.
Variable Score Negative (%) Positive (%) Total
D-dimer   0 33 (94.3) 2 (5.7) 35
   3 26 (76.5) 8 (23.5) 34
   5 17 (60.7) 11 (39.3) 28
   6 2 (50.0) 2 (50.0)   4
   8 13 (43.3) 17 (56.7) 30
 11 3 (21.4) 11 (78.6) 14
P-selectin   0 19 (86.4) 3 (13.6) 22
   2 6 (75.0) 2 (25.0)   8
   3 15 (88.2) 2 (11.8) 17
   4 3 (100.0) 0 (0.0)   3
   5 16 (61.5) 10 (38.5) 26
   6 6 (60.0) 4 (40.0) 10
   7 4 (44.4) 5 (55.6)   9
   8 2 (40.0) 3 (60.0)   5
   9 1 (11.1) 8 (88.9)   9
 10 0 (0.0) 2 (100.0)   2
 12 1 (16.7) 5 (83.3)   6
Table VII. Predictive score for TEE risk.
Variable Score Risk classification Negative (%) Positive (%) Total
D-dimer
 0 to 3 Low risk 59 (85.5) 10 (14.5) 69
 5 to 6 Moderate risk 19 (59.4) 13 (40.6) 32
 8 High risk 13 (43.3) 17 (56.7) 30
 9 Very high risk 3 (21.4) 11 (78.6) 14
P-selectin 0 to 4 Low risk 43 (86.0) 7 (14.0) 50
 5 to 6 Moderate risk 22 (61.1) 14 (38.9) 36
 7 to 8 High risk 6 (42.9) 8 (57.1) 14
 ≥9 Very high risk 2 (11.8) 15 (88.2) 17
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The literature provides robust data concerning the 
association between decreased mobility and occurrence of 
TEEs (2,17,45). A large number of patients presented ECOG 
scores of 0 or 1 (55.22%). A total of 55.96% of the patients 
had restriction (ECOG 2, 3 and 4) in the positive group, with 
the smallest percentage being identified in the negative group 
(38.3%). Similar reasoning can be applied to mobility, since 
many patients had restrictions on their locomotion (35.14% 
in the positive group and 76.59% in the negative group), 
confirming once again that there is a correlation between 
restriction on movement and the occurrence of TEE.
Although obesity is a risk factor for TEE (18), 22.71% 
of the patients had obesity grades I, II or III (the BMI was 
classified as follows: <18, underweight; 18-24.9, normal 
weight; 25-29.9, obesity grade I; 30-34.9, obesity grade II; 
≥30, obesity grade III); the BMI values were 14.02% for the 
positive group, and 27.26% for the negative group. Therefore, 
the obesity rate was lower in the TEE positive group. It is 
possible that this association has been influenced by other 
factors, as patients with metastases, clearly weakened, or at 
an advanced stage of the cancer disease are at higher risk for 
TEEs; however, they are also underweight, due to the state of 
patient consumption.
The occurrence of TEEs in the cancer population may 
reach 25%. In the current study, 18 (16.82%) of the 107 patients 
who were receiving anticoagulant therapy were confirmed to 
have TEEs due to previous TEE treatment.
The laboratory tests revealed the association between 
hemoglobin and hematocrit with TEEs, possibly due to the 
correlation of a decreased in the levels of hemoglobin with 
advanced cancer and, consequently, a higher risk of progressing 
to TEEs. IL-6, D-dimer and P-selectin levels were statistically 
different between the positive and negative groups, which 
revealed a potential use of these markers as ancillary tests for 
TEEs in patients with cancer.
The results from the present analysis disclosed several 
interesting laboratory characteristics that partly differed 
from those reported in the literature. Among them, the most 
intriguing was the value identified for P-selectin. While 
retaining the ability to differentiate between the groups with 
or without TEEs, the average values that were identified were 
much lower than had been expected. Also, the ROC curve 
indicated cut-off values for the D-dimer evaluation that 
were higher than those reported in the literature (633 ng/ml 
compared with 500 ng /ml, respectively).
In conclusion, despite being associated with more 
advanced tumors and more features of aggressive 
behavior (46), in terms of elevated serum levels of FBN, no 
association with TEEs was identified. Similar findings were 
observed regarding other parameters generally associated 
with TEEs (47), such as AFXa. The levels of hsCRP were 
revealed to be much higher than the values of reference, which 
was as expected (35), although these were not of value in 
potentially being of use for the prediction of TEEs. However, 
the cut-off value of P-selectin for patients with cancer was 
different from that reported in the literature in the general 
population, and the model using D-dimer and P-selectin has 
been revealed in the present study to be potentially suitable 
for use in a panel of tests to predict TEEs, either indepen-
dently or in a prediction score.
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